Cargando…

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancer cases and ranks as the second leading cause of cancer related death. Multiple receptor tyrosine kinases such as EGFR, FGFR and c-MET have been shown to drive tumorigenesis and progression of HCC. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Shan, Li, Na, Zhang, Xiaozhe, Chen, Jingyi, Ko, Ben C.B., Zhao, Yanxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791588/ https://www.ncbi.nlm.nih.gov/pubmed/36578529 http://dx.doi.org/10.1016/j.bbrep.2022.101412

Ejemplares similares

Perturbation of Autophagy by a Beclin 1-Targeting Stapled Peptide Induces Mitochondria Stress and Inhibits Proliferation of Pancreatic Cancer Cells
por: Li, Na, et al.
Publicado: (2023)

Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides
por: To, Jeffrey C., et al.
Publicado: (2023)

An autophagy-inducing stapled peptide induces mitochondria dysfunction and triggers autotic cell death in triple-negative breast cancer
por: Zhang, Xiaozhe, et al.
Publicado: (2023)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
por: Lee, Joycelyn J. X., et al.
Publicado: (2015)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Firtina Karagonlar, Zeynep, et al.
Publicado: (2016)

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017)

Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET
por: Greenall, Sameer A., et al.
Publicado: (2012)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
por: Ma, Xiao-Lu, et al.
Publicado: (2023)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Epigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma
por: Ogunwobi, Olorunseun O., et al.
Publicado: (2013)

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
por: Bouattour, Mohamed, et al.
Publicado: (2018)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met(+) Hepatocellular Carcinoma
por: Steinway, Steven N., et al.
Publicado: (2015)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

Novel Peptide CM 7 Targeted c-Met with Antitumor Activity
por: Xia, Chunlei, et al.
Publicado: (2020)

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Jet/MET + b/c tagging
por: Komaragiri, Jyothsna Rani
Publicado: (2022)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

c-Met and miRs in Cancer
por: Giglio, Simona, et al.
Publicado: (2015)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Induction of tumor initiation is dependent on CD44s in c-Met(+) hepatocellular carcinoma
por: Dang, Hien, et al.
Publicado: (2015)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
por: Hu, Chi-Tan, et al.
Publicado: (2017)

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
por: Shao, Weiqing, et al.
Publicado: (2019)

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
por: Decaens, Thomas, et al.
Publicado: (2021)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

c-Met is essential for wound healing in the skin
por: Chmielowiec, Jolanta, et al.
Publicado: (2007)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_snh311puemtq37bsnkta0tfvau